Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
STRATEGIC ANALYSIS • MONALEESA-3

Ribociclib + Fulvestrant: Maintenance of Quality of Life in Advanced Breast Cancer

Analysis of patient-reported outcomes (PROs) demonstrates that adding Ribociclib to Fulvestrant does not deteriorate Quality of Life compared to placebo, while offering a trend towards delayed pain progression.

Source:
DOI:

Study Design & Population

Risk of Quality of Life Deterioration (Hazard Ratio)

Lower HR = Better Outcome
Conclusion: Hazard Ratios < 1.0 indicate a trend favoring Ribociclib in delaying deterioration, though confidence intervals cross 1 (statistically non-significant).

Median Time to Definitive Deterioration (Months)

Baseline Global Health Status (EORTC QLQ-C30)

Key Performance Indicators

Clinical Implications

Data Appendix

Metric Group Value Unit Source
Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode